Newest Rating: Laurentian Bank Gives Syncordia Technologies and Healthcare (TSE:SYN) Lower Rating. Lost Its Buy Rating

November 25, 2016 - By Michael Collier

Newest Rating: Laurentian Bank Gives Syncordia Technologies and Healthcare (TSE:SYN) Lower Rating. Lost Its Buy Rating

Syncordia Technologies and Healthcare (TSE:SYN) Downgrade

Expert analysts at Laurentian Bank’s research division cut Syncordia Technologies and Healthcare (TSE:SYN)‘s stock rating from Buy to Speculative Buy on Friday morning.

The stock increased 1.23% or $0.011 on November 25, hitting $0.881. About 435,594 shares traded hands. Synthetic Biologics Inc (TSE:SYN) has risen 6.00% since October 26, 2016 and is uptrending. It has outperformed by 0.59% the S&P500.

Analysts await Synthetic Biologics Inc (NYSEMKT:SYN) to report earnings on March, 9. They expect $-0.09 EPS, up 25.00% or $0.03 from last year’s $-0.12 per share. After $-0.09 actual EPS reported by Synthetic Biologics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Synthetic Biologics, Inc. is a clinical-stage company. The company has a market cap of $99.28 million. The Firm is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. It currently has negative earnings. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation , and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).

According to Zacks Investment Research, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan.”

SYN Company Profile

Synthetic Biologics, Inc., incorporated on December 23, 2008, is a clinical-stage company. The Firm is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). The Company’s other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Firm is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU). The Company’s IBS-C and CDI/AAD programs are focused on protecting the gut microbiome, or gut flora.

Another recent and important Synthetic Biologics Inc (NYSEMKT:SYN) news was published by Prnewswire.com which published an article titled: “Synthetic Biologics Reports Third Quarter 2016 Operational Highlights and …” on November 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>